Ghost Tree Capital, LLC historic quarter change: USA Stocks, Added
In share positions in stocks (listed in the US), over 14 quarters from 2013-12-31 to 2024-09-30, Ghost Tree Capital, LLC opened 144 positions, added to 89, reduced 77 and sold out of 127.
- Q3 2024: Stock JANX; Country of operation United States; Class COM; Shares before 50,000.
- Q3 2024: Stock SRPT; Country of operation United States; Class COM; Shares before 55,000.
- Q3 2024: Stock TARS; Country of operation United States; Class COM; Shares before 235,000.
- Q3 2024: Stock VKTX; Country of operation United States; Class COM; Shares before 95,000.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1595851), 14 quarters: Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-12); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-17); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-09-09); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-18); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2013-12-31. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q3 2024 | JANX
JANUX THERAPEUTICS INC | United States | COM | 50,000 | 190,000 | +140,000 | $2,094,500 | $8,631,700 | +$6,537,200 | 2024-11-14 |
|---|
| Q3 2024 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM | 55,000 | 120,000 | +65,000 | $8,690,000 | $14,986,800 | +$6,296,800 | 2024-11-14 |
|---|
| Q3 2024 | TARS
TARSUS PHARMACEUTICALS INC | United States | COM | 235,000 | 350,000 | +115,000 | $6,387,300 | $11,511,500 | +$5,124,200 | 2024-11-14 |
|---|
| Q3 2024 | VKTX
VIKING THERAPEUTICS INC | United States | COM | 95,000 | 140,000 | +45,000 | $5,035,950 | $8,863,400 | +$3,827,450 | 2024-11-14 |
|---|
| Q3 2024 | ANNX
ANNEXON INC | United States | COM | 310,000 | 650,000 | +340,000 | $1,519,000 | $3,848,000 | +$2,329,000 | 2024-11-14 |
|---|
| Q3 2024 | ARVN
ARVINAS INC | United States | COM | 75,000 | 145,000 | +70,000 | $1,996,500 | $3,571,350 | +$1,574,850 | 2024-11-14 |
|---|
| Q3 2024 | TSHA
TAYSHA GENE THERAPIES INC | United States | COM SHS | 1,250,000 | 2,150,000 | +900,000 | $2,800,000 | $4,321,500 | +$1,521,500 | 2024-11-14 |
|---|
| Q3 2024 | SNDX
SYNDAX PHARMACEUTICALS INC | United States | COM | 350,000 | 450,000 | +100,000 | $7,185,500 | $8,662,500 | +$1,477,000 | 2024-11-14 |
|---|
| Q3 2024 | TNYA
TENAYA THERAPEUTICS INC | United States | COM | 1,350,000 | 1,500,000 | +150,000 | $4,185,000 | $2,895,000 | -$1,290,000 | 2024-11-14 |
|---|
| Q3 2024 | INSM
INSMED INC | United States | COM PAR $.01 | 65,000 | 75,000 | +10,000 | $4,355,000 | $5,475,000 | +$1,120,000 | 2024-11-14 |
|---|
| Q3 2024 | RZLT
REZOLUTE INC | United States | COM NEW | 1,421,501 | 1,474,995 | +53,494 | $6,112,454 | $7,153,726 | +$1,041,272 | 2024-11-14 |
|---|
| Q3 2024 | BBIO
BRIDGEBIO PHARMA INC | United States | COM | 140,000 | 175,000 | +35,000 | $3,546,200 | $4,455,500 | +$909,300 | 2024-11-14 |
|---|
| Q3 2024 | RGNX
REGENXBIO INC | United States | COM | 170,000 | 265,000 | +95,000 | $1,989,000 | $2,779,850 | +$790,850 | 2024-11-14 |
|---|
| Q3 2024 | KRRO
KORRO BIO INC | United States | COM | 100,000 | 110,000 | +10,000 | $3,387,000 | $3,676,200 | +$289,200 | 2024-11-14 |
|---|
| Q3 2024 | NUVB
NUVATION BIO INC | United States | COM CL A | 1,150,000 | 1,350,000 | +200,000 | $3,358,000 | $3,091,500 | -$266,500 | 2024-11-14 |
|---|
| Q2 2024 | CRBP
CORBUS PHARMACEUTICALS HLDGS | United States | COM NEW | 56,941 | 175,000 | +118,059 | $2,234,365 | $7,918,750 | +$5,684,385 | 2024-08-14 |
|---|
| Q2 2024 | CGON
CG ONCOLOGY INC | United States | COM | 75,000 | 260,000 | +185,000 | $3,292,500 | $8,208,200 | +$4,915,700 | 2024-08-14 |
|---|
| Q2 2024 | PCVX
VAXCYTE INC | United States | COM | 95,000 | 150,000 | +55,000 | $6,489,450 | $11,326,500 | +$4,837,050 | 2024-08-14 |
|---|
| Q2 2024 | OLMA
OLEMA PHARMACEUTICALS INC | United States | COM | 200,000 | 550,000 | +350,000 | $2,264,000 | $5,951,000 | +$3,687,000 | 2024-08-14 |
|---|
| Q2 2024 | SLNO
SOLENO THERAPEUTICS INC | United States | COM | 200,000 | 300,000 | +100,000 | $8,560,000 | $12,240,000 | +$3,680,000 | 2024-08-14 |
|---|
| Q2 2024 | SNDX
SYNDAX PHARMACEUTICALS INC | United States | COM | 150,000 | 350,000 | +200,000 | $3,570,000 | $7,185,500 | +$3,615,500 | 2024-08-14 |
|---|
| Q2 2024 | IMVT
IMMUNOVANT INC | United States | COM | 125,000 | 260,000 | +135,000 | $4,038,750 | $6,864,000 | +$2,825,250 | 2024-08-14 |
|---|
| Q2 2024 | APLS
APELLIS PHARMACEUTICALS INC | United States | COM | 130,000 | 135,000 | +5,000 | $7,641,400 | $5,178,600 | -$2,462,800 | 2024-08-14 |
|---|
| Q2 2024 | SYRE
SPYRE THERAPEUTICS INC | United States | COM NEW | 100,000 | 250,237 | +150,237 | $3,793,000 | $5,883,072 | +$2,090,072 | 2024-08-14 |
|---|
| Q2 2024 | BHVN
BIOHAVEN LTD | United States | COM | 285,000 | 490,000 | +205,000 | $15,586,650 | $17,007,900 | +$1,421,250 | 2024-08-14 |
|---|
| Q2 2024 | CRNX
CRINETICS PHARMACEUTICALS IN | United States | COM | 200,000 | 240,000 | +40,000 | $9,362,000 | $10,749,600 | +$1,387,600 | 2024-08-14 |
|---|
| Q2 2024 | NGNE
NEUROGENE INC | | COM | 25,000 | 70,000 | +45,000 | $1,272,500 | $2,547,300 | +$1,274,800 | 2024-08-14 |
|---|
| Q2 2024 | PHAT
PHATHOM PHARMACEUTICALS INC | United States | COM | 485,000 | 600,000 | +115,000 | $5,150,700 | $6,180,000 | +$1,029,300 | 2024-08-14 |
|---|
| Q2 2024 | VKTX
VIKING THERAPEUTICS INC | United States | COM | 73,002 | 95,000 | +21,998 | $5,986,164 | $5,035,950 | -$950,214 | 2024-08-14 |
|---|
| Q2 2024 | RGNX
REGENXBIO INC | United States | COM | 120,000 | 170,000 | +50,000 | $2,528,400 | $1,989,000 | -$539,400 | 2024-08-14 |
|---|
| Q2 2024 | CYTK
CYTOKINETICS INC | United States | COM NEW | 20,000 | 33,200 | +13,200 | $1,402,200 | $1,798,776 | +$396,576 | 2024-08-14 |
|---|
| Q2 2024 | ARVN
ARVINAS INC | United States | COM | 40,000 | 75,000 | +35,000 | $1,651,200 | $1,996,500 | +$345,300 | 2024-08-14 |
|---|
| Q2 2024 | TNYA
TENAYA THERAPEUTICS INC | United States | COM | 775,000 | 1,350,000 | +575,000 | $4,053,250 | $4,185,000 | +$131,750 | 2024-08-14 |
|---|
| Q2 2024 | ATYR
ATYR PHARMA INC | United States | COM NEW | 600,000 | 800,000 | +200,000 | $1,170,000 | $1,248,000 | +$78,000 | 2024-08-14 |
|---|
| Q2 2024 | TSHA
TAYSHA GENE THERAPIES INC | United States | COM SHS | 950,000 | 1,250,000 | +300,000 | $2,726,500 | $2,800,000 | +$73,500 | 2024-08-14 |
|---|
| Q1 2024 | MLTX
MOONLAKE IMMUNOTHERAPEUTICS | Switzerland | CLASS A ORD | 80,000 | 300,000 | +220,000 | $4,831,200 | $15,069,000 | +$10,237,800 | 2024-05-15 |
|---|
| Q1 2024 | TGTX
TG THERAPEUTICS INC | United States | COM | 250,000 | 825,000 | +575,000 | $4,270,000 | $12,548,250 | +$8,278,250 | 2024-05-15 |
|---|
| Q1 2024 | CRNX
CRINETICS PHARMACEUTICALS IN | United States | COM | 65,000 | 200,000 | +135,000 | $2,312,700 | $9,362,000 | +$7,049,300 | 2024-05-15 |
|---|
| Q1 2024 | ROIV
ROIVANT SCIENCES LTD | | SHS | 600,000 | 1,300,000 | +700,000 | $6,738,000 | $13,702,000 | +$6,964,000 | 2024-05-15 |
|---|
| Q1 2024 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM | 100,000 | 125,000 | +25,000 | $9,643,000 | $16,182,500 | +$6,539,500 | 2024-05-15 |
|---|
| Q1 2024 | SVRA
SAVARA INC | United States | COM | 750,000 | 1,600,000 | +850,000 | $3,525,000 | $7,968,000 | +$4,443,000 | 2024-05-15 |
|---|
| Q1 2024 | VRDN
VIRIDIAN THERAPEUTICS INC | United States | COM | 300,000 | 625,000 | +325,000 | $6,534,000 | $10,943,750 | +$4,409,750 | 2024-05-15 |
|---|
| Q1 2024 | SLNO
SOLENO THERAPEUTICS INC | United States | COM | 112,385 | 200,000 | +87,615 | $4,523,496 | $8,560,000 | +$4,036,504 | 2024-05-15 |
|---|
| Q1 2024 | BHVN
BIOHAVEN LTD | United States | COM | 275,000 | 285,000 | +10,000 | $11,770,000 | $15,586,650 | +$3,816,650 | 2024-05-15 |
|---|
| Q1 2024 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM | 27,500 | 60,000 | +32,500 | $5,263,775 | $8,967,000 | +$3,703,225 | 2024-05-15 |
|---|
| Q1 2024 | AXSM
AXSOME THERAPEUTICS INC | United States | COM | 165,000 | 210,000 | +45,000 | $13,132,350 | $16,758,000 | +$3,625,650 | 2024-05-15 |
|---|
| Q1 2024 | CABA
CABALETTA BIO INC | United States | COM | 150,000 | 375,000 | +225,000 | $3,405,000 | $6,397,500 | +$2,992,500 | 2024-05-15 |
|---|
| Q1 2024 | ACAD
ACADIA PHARMACEUTICALS INC | United States | COM | 50,000 | 225,000 | +175,000 | $1,565,500 | $4,160,250 | +$2,594,750 | 2024-05-15 |
|---|
| Q1 2024 | PCVX
VAXCYTE INC | United States | COM | 70,000 | 95,000 | +25,000 | $4,396,000 | $6,489,450 | +$2,093,450 | 2024-05-15 |
|---|
| Q1 2024 | REPL
REPLIMUNE GROUP INC | United States | COM | 400,000 | 650,000 | +250,000 | $3,372,000 | $5,310,500 | +$1,938,500 | 2024-05-15 |
|---|
| Q1 2024 | COGT
COGENT BIOSCIENCES INC | United States | COM | 195,000 | 450,000 | +255,000 | $1,146,600 | $3,024,000 | +$1,877,400 | 2024-05-15 |
|---|
| Q1 2024 | PHAT
PHATHOM PHARMACEUTICALS INC | United States | COM | 385,241 | 485,000 | +99,759 | $3,517,250 | $5,150,700 | +$1,633,450 | 2024-05-15 |
|---|
| Q1 2024 | KALV
KALVISTA PHARMACEUTICALS INC | United States | COM | 130,036 | 200,000 | +69,964 | $1,592,941 | $2,372,000 | +$779,059 | 2024-05-15 |
|---|
| Q1 2024 | CYTK
CYTOKINETICS INC | United States | COM NEW | 10,000 | 20,000 | +10,000 | $834,900 | $1,402,200 | +$567,300 | 2024-05-15 |
|---|
| Q1 2024 | BBIO
BRIDGEBIO PHARMA INC | United States | COM | 125,000 | 175,000 | +50,000 | $5,046,250 | $5,411,000 | +$364,750 | 2024-05-15 |
|---|
| Q3 2016 | BCRX
BIOCRYST PHARMACEUTICALS | United States | COM | 1,700,000 | 1,800,000 | +100,000 | $4,828,000 | $7,938,000 | +$3,110,000 | 2016-11-14 |
|---|
| Q3 2016 | BSX
BOSTON SCIENTIFIC CORP | United States | COM | 325,000 | 400,000 | +75,000 | $7,595,000 | $9,520,000 | +$1,925,000 | 2016-11-14 |
|---|
| Q3 2016 | VCYT
VERACYTE INC | United States | COM | 341,708 | 364,000 | +22,292 | $1,719,000 | $2,770,000 | +$1,051,000 | 2016-11-14 |
|---|
| Q2 2016 | BMRN
BIOMARIN PHARMACEUTICAL INC | United States | COM | 40,000 | 110,000 | +70,000 | $3,299,000 | $8,558,000 | +$5,259,000 | 2016-08-12 |
|---|
| Q4 2015 | AMGN
AMGEN INC | United States | COM | 50,000 | 75,000 | +25,000 | $6,916,000 | $12,175,000 | +$5,259,000 | 2016-02-17 |
|---|
| Q4 2015 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM | 10,000 | 100,000 | +90,000 | $321,000 | $3,858,000 | +$3,537,000 | 2016-02-17 |
|---|
| Q4 2015 | INCY
INCYTE CORP | United States | COM | 25,000 | 50,000 | +25,000 | $2,758,000 | $5,423,000 | +$2,665,000 | 2016-02-17 |
|---|
| Q4 2015 | VCYT
VERACYTE INC | United States | COM | 202,800 | 350,000 | +147,200 | $951,000 | $2,520,000 | +$1,569,000 | 2016-02-17 |
|---|
| Q4 2015 | CPRX
CATALYST PHARMACEUTICALS INC | United States | COM | 350,000 | 376,000 | +26,000 | $1,050,000 | $921,000 | -$129,000 | 2016-02-17 |
|---|
| Q3 2015 | BCRX
BIOCRYST PHARMACEUTICALS INC | United States | COM | 45,000 | 225,000 | +180,000 | $672,000 | $2,565,000 | +$1,893,000 | 2015-11-16 |
|---|
| Q3 2015 | VCYT
VERACYTE INC | United States | COM | 78,386 | 202,800 | +124,414 | $873,000 | $951,000 | +$78,000 | 2015-11-16 |
|---|
| Q2 2015 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM | 40,000 | 90,000 | +50,000 | $4,177,000 | $10,788,000 | +$6,611,000 | 2015-09-09 |
|---|
| Q2 2015 | FOLD
AMICUS THERAPEUTICS INC | United States | COM | 350,000 | 375,000 | +25,000 | $3,808,000 | $5,306,000 | +$1,498,000 | 2015-09-09 |
|---|
| Q2 2015 | PTCT
PTC THERAPEUTICS INC | United States | COM | 60,000 | 100,000 | +40,000 | $3,651,000 | $4,813,000 | +$1,162,000 | 2015-09-09 |
|---|
| Q1 2015 | MMSI
MERIT MED SYS INC | United States | COM | 75,000 | 300,000 | +225,000 | $1,300,000 | $5,775,000 | +$4,475,000 | 2015-05-15 |
|---|
| Q1 2015 | ZBH
ZIMMER HLDGS INC | United States | COM | 86,200 | 100,000 | +13,800 | $9,777,000 | $11,752,000 | +$1,975,000 | 2015-05-15 |
|---|
| Q1 2015 | FOLD
AMICUS THERAPEUTICS INC | United States | COM | 300,000 | 350,000 | +50,000 | $2,496,000 | $3,808,000 | +$1,312,000 | 2015-05-15 |
|---|
| Q4 2014 | ZBH
ZIMMER HLDGS INC | United States | COM | 50,000 | 86,200 | +36,200 | $5,028,000 | $9,777,000 | +$4,749,000 | 2015-02-18 |
|---|
| Q4 2014 | PBYI
PUMA BIOTECHNOLOGY INC | United States | COM | 5,000 | 30,000 | +25,000 | $1,193,000 | $5,678,000 | +$4,485,000 | 2015-02-18 |
|---|
| Q4 2014 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM | 35,000 | 55,000 | +20,000 | $2,734,000 | $5,335,000 | +$2,601,000 | 2015-02-18 |
|---|
| Q4 2014 | PTCT
PTC THERAPEUTICS INC | United States | COM | 50,000 | 85,000 | +35,000 | $2,201,000 | $4,400,000 | +$2,199,000 | 2015-02-18 |
|---|
| Q3 2014 | HCA
HCA HOLDINGS INC | United States | COM | 45,000 | 60,000 | +15,000 | $2,537,000 | $4,231,000 | +$1,694,000 | 2014-11-14 |
|---|
| Q3 2014 | PBYI
PUMA BIOTECHNOLOGY INC | United States | COM | 1,000 | 5,000 | +4,000 | $66,000 | $1,193,000 | +$1,127,000 | 2014-11-14 |
|---|
| Q3 2014 | EW
EDWARDS LIFESCIENCES CORP | United States | COM | 20,000 | 25,000 | +5,000 | $1,717,000 | $2,554,000 | +$837,000 | 2014-11-14 |
|---|
| Q3 2014 | BRKR
BRUKER CORP | United States | COM | 130,000 | 140,000 | +10,000 | $3,155,000 | $2,592,000 | -$563,000 | 2014-11-14 |
|---|
| Q3 2014 | ATRC
ATRICURE INC | United States | COM | 225,000 | 250,000 | +25,000 | $4,136,000 | $3,680,000 | -$456,000 | 2014-11-14 |
|---|
| Q2 2014 | ATRC
ATRICURE INC | United States | COM | 85,000 | 225,000 | +140,000 | $1,599,000 | $4,136,000 | +$2,537,000 | 2014-08-14 |
|---|
| Q2 2014 | INSM
INSMED INC | United States | COM PAR $.01 | 135,000 | 200,000 | +65,000 | $2,570,000 | $3,996,000 | +$1,426,000 | 2014-08-14 |
|---|
| Q2 2014 | CYH
COMMUNITY HEALTH SYS INC NEW | United States | COM | 80,000 | 100,000 | +20,000 | $3,134,000 | $4,537,000 | +$1,403,000 | 2014-08-14 |
|---|
| Q2 2014 | BRKR
BRUKER CORP | United States | COM | 90,000 | 130,000 | +40,000 | $2,051,000 | $3,155,000 | +$1,104,000 | 2014-08-14 |
|---|
| Q2 2014 | ENTA
ENANTA PHARMACEUTICALS INC | United States | COM | 35,000 | 50,000 | +15,000 | $1,400,000 | $2,154,000 | +$754,000 | 2014-08-14 |
|---|
| Q2 2014 | CPRX
CATALYST PHARM PARTNERS INC | United States | COM | 200,000 | 437,296 | +237,296 | $452,000 | $1,106,000 | +$654,000 | 2014-08-14 |
|---|
| Q1 2014 | CYH
COMMUNITY HEALTH SYS INC NEW | United States | COM | 70,000 | 80,000 | +10,000 | $2,749,000 | $3,134,000 | +$385,000 | 2014-05-15 |
|---|
| Q1 2014 | CPRX
CATALYST PHARM PARTNERS INC | United States | COM | 175,000 | 200,000 | +25,000 | $341,000 | $452,000 | +$111,000 | 2014-05-15 |
|---|